- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02677857
Developing a Healthy Lifestyle in Breast Cancer Survivors
At this time, no study has examined the effect of a lifestyle intervention with a reduced Sedentary Behavior (SB) prescription on overall physical activity, weight loss, metabolic dysfunction, and inflammation in breast cancer survivors. Thus, in collaboration with University of Tennessee Medical Center's (UTMC) Cancer Institute, investigators propose to randomize 30 female breast cancer survivors (history of breast cancer stages I [> 1 cm], II, or III) with a body mass index (BMI) between 25 and 45 kg/m2 who are sedentary (engage in > 8 hours a day of SB) and inactive (engage in < 100 min/wk MVPA) to one of three, 3-month conditions:
- lifestyle intervention (Lifestyle) (increase MVPA to > 200 min/wk);
- lifestyle intervention with a reduced SB prescription (Lifestyle+SB) (increase MVPA to > 200 min/wk and reduce SB by 2 hrs/day); or
- weight management education materials provided via mailed newsletter (Newsletter).
Lifestyle and Lifestyle+SB will receive a standard dietary (low-calorie [1200-1500 kcal/day], low-fat [<30% calories from fat]) prescription that emphasizes intake of fruits, vegetables, and whole grains, and a cognitive behavioral intervention to assist with meeting activity and diet goals. Dependent variables, measured at 0 and 3 months, include objectively measured SB, LPA, MVPA, and total activity via accelerometry; self-reported SB; percent weight loss; insulin and glucose, and leptin and C-reactive protein (CRP) (biomarkers of cancer prognosis that have been found to be positively related to SB and/or adiposity); diet; body composition; and fitness.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37996
- Healthy Eating and Activity Laboratory
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age between 18 and 65 yrs
- BMI between 25 and 45 kg/m2
- history of breast cancer (stages I [> 1 cm], II, or III) diagnosed within the previous 5 years
- completion of initial therapies
- engage in > 8 hours a day of SB
- engage in < 100 min/wk MVPA.
Exclusion Criteria:
- report a heart condition, chest pain during periods of activity or rest, or loss of consciousness on the Physical Activity Readiness Questionnaire (PAR-Q)25 (The Health Screening Questionnaire will also be used to identify individuals with joint problems, prescription medication usage, or other medical conditions that could limit exercise, and these individuals will be required to obtain written physician consent to participate - the two questionnaires are found in questions 4-11 in the phone screen in Appendix B)
- report being unable to walk for 2 blocks (1/4 mile) without stopping
- report major psychiatric diseases or organic brain syndromes
- report a serious medical condition in which weight loss is contraindicated
- are currently participating in a weight loss program and/or taking weight loss medication or lost > 5% of body weight during the past 6 months
- have had bariatric surgery or are planning to have bariatric surgery in the next 6 months
- are participating in a program to increase physical activity and/or decrease sedentary time
- intend to move outside of the metropolitan area within the time frame of the investigation
- are pregnant, lactating, < 6 months post-partum, or plan to become pregnant during the investigation
- are unwilling to attend sessions and/or unwilling to be randomized to any treatment condition;
- do not own a smartphone that will run the app required for the Polar® Loop device;
- are unwilling to use MyFitnessPal or the Polar® Loop device app for smartphones; or
- have a metal allergy or are not able to wear anything on an upper arm (which would prevent the ability of participant to wear the SenseWear® armband from BodyMedia® used in the proposed study).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Lifestyle
Participants will be educated on the relationship between MVPA and improved health outcomes, including weight management, and cancer survivorship.
The goal will be to increase MVPA to > 40 min/day 5 times/wk As participants will be overweight/obese, inactive, and coming into the program with different levels of baseline fitness and time since last cancer treatment, participants will shape their MVPA to meet the targeted goals.
Initially, participants will be encouraged to complete MVPA > 10 min/day 5 times/wk, and then progressively increase MVPA by 5 min/day every week until reaching the intervention goal (week 7 of the 12 week intervention).
Participants will be encouraged to do brisk walking and be allowed to accumulate time spent being physically active by engaging in multiple short bouts (i.e., > 10 min in length).
Any MVPA in bouts of > 10 min in length will be counted towards the MVPA goal.
Participants will self-monitor their MVPA using the Polar® Loop tracking system.
|
Participants in these conditions will receive standard care and one of the Lifestyle conditions.
There are several components that will be identical for both Lifestyle conditions.
These components include treatment structure, dietary goals, and cognitive behavioral strategies.
|
|
Active Comparator: Lifestyle + SB
Participants will receive everything that is described in Lifestyle.
Additionally, they will be educated on the relationship between SB and weight management, and cancer survivorship risk.
The goal will be to reduce sedentary time by > 2 hrs/day or > 14 hrs/wk.
Participants will shape towards the goal.
Baseline measures will be used as the starting point from where to calculate the 2 hrs/day reduction, providing participants with a total SB goal per day.
For example, if baseline measures indicate that a participant has a mean daily SB amount of 9.75 hrs, the participant's SB goal will be 7.75 hrs/day.
To achieve that goal, participants will reduce SB by 20 minutes a day, starting week 2, with a decrease of an additional 20 minutes/day occurring weekly until the SB goal is achieved (week 7 of the 12 week intervention.
Participants will self-monitor their SB using the Polar® Loop tracking system.
|
Participants in these conditions will receive standard care and one of the Lifestyle conditions.
There are several components that will be identical for both Lifestyle conditions.
These components include treatment structure, dietary goals, and cognitive behavioral strategies.
|
|
No Intervention: Newsletter
Participants in this condition will receive standard care and every month they will receive a newsletter that provides information and tips about healthy eating and activity behaviors.
This newsletter will include information on myPlate,28 activity guidelines,29 reading food labels, healthy recipes, and seasonal activity suggestions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measures of activity by Armband
Time Frame: change from baseline to 12 weeks
|
Participants will wear the SenseWear Armband (SWA) for data collection of time spent engaging in physical activity per day.
|
change from baseline to 12 weeks
|
|
Weight
Time Frame: change from baseline to 12 weeks
|
Weight will be assessed by an electronic scale.
|
change from baseline to 12 weeks
|
|
Measures of diet
Time Frame: change from baseline to 12 weeks
|
Diet will be assessed by 3-day food records (2 weekdays and 1 weekend day).
Each record will be completed using the Nutrition Data System Software for Research (NDS-R) developed by the Nutrition Coordinating Center, University of Minnesota, Minneapolis, Minnesota.
|
change from baseline to 12 weeks
|
|
Fitness (The 6 Minute Walk Test (6MWT))
Time Frame: change from baseline to 12 weeks
|
The 6 Minute Walk Test (6MWT) is well tolerated by participants who are obese.
Participants will walk as quickly as possible, without jogging or running, around two cones placed 60 m apart for 6 min.
The primary measure will be distance walked.
The 6MWT has been significantly correlated to peak oxygen uptake (VO2) values from a cycle ergometer test (r = .73,
p < 0.001).
The 6MWT has been shown to measure enhanced physical performance beyond that which occurs from weight loss itself in participants with obesity.
Standard safety protocols will be used for participants that Dr. Bell considers appropriate for testing.
|
change from baseline to 12 weeks
|
|
Physical activity by Questionnaire
Time Frame: change from baseline to 12 weeks
|
Participants will complete the Past-day Adults' Sedentary Time (PAST), a seven-item questionnaire that asks questions about sedentary behaviors that have occurred during the previous day.
|
change from baseline to 12 weeks
|
|
Insulin
Time Frame: change from baseline to 12 weeks
|
Blood samples will be obtained from over-night fasted participants who have not engaged in MVPA and analyzed at UTMC using standard procedures.
|
change from baseline to 12 weeks
|
|
Glucose
Time Frame: change from baseline to 12 weeks
|
Blood samples will be obtained from over-night fasted participants who have not engaged in MVPA and analyzed at UTMC using standard procedures.
|
change from baseline to 12 weeks
|
|
Leptin
Time Frame: change from baseline to 12 weeks
|
Blood samples will be obtained from over-night fasted participants who have not engaged in MVPA and analyzed at UTMC using standard procedures.
|
change from baseline to 12 weeks
|
|
C-Reactive Protein
Time Frame: change from baseline to 12 weeks
|
Blood samples will be obtained from over-night fasted participants who have not engaged in MVPA and analyzed at UTMC using standard procedures.
|
change from baseline to 12 weeks
|
|
Height
Time Frame: baseline
|
Height will be assessed using a stadiometer at baseline
|
baseline
|
|
BMI
Time Frame: change from baseline to 12 weeks
|
BMI (kg/m2) will be calculated from height and weight measurements.
|
change from baseline to 12 weeks
|
|
Waist circumference
Time Frame: change from baseline to 12 weeks
|
waist measurement
|
change from baseline to 12 weeks
|
|
Percent body fat
Time Frame: change from baseline to 12 weeks
|
Percent body fat will be assessed by bioelectrical impedance analysis (BIA), using the foot to foot pressure contact electrode BIA technique (Tanita TBF-300A model) following standard protocol
|
change from baseline to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Completion of self-monitoring records
Time Frame: 12 weeks
|
Number of weekly records of self-monitoring of diet and activity completed and turned in.
|
12 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hollie Raynor, University of Tennessee
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UTKIRB-15-02602-FB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Common intervention components for Lifestyle
-
The University of Tennessee, KnoxvilleActive, not recruiting
-
UMC UtrechtTilburg University; VU University of Amsterdam; Ede Christian University of Applied...Recruiting
-
University of Alabama at BirminghamCompletedObesityUnited States
-
LMC Diabetes & Endocrinology Ltd.Public Health Agency of Canada (PHAC)Active, not recruiting
-
Université de SherbrookeCanadian Institutes of Health Research (CIHR); Ministere de la Sante et des...CompletedObesity | Polycystic Ovary Syndrome | Female InfertilityCanada
-
Maastricht University Medical CenterMaastricht UniversityCompletedChildhood Obesity | Underweight | Overweight (BMI > 25)India
-
Xuanwu Hospital, BeijingCompletedPolycystic Ovary Syndrome (PCOS)China
-
Stanford UniversityCompleted
-
National Yang Ming Chiao Tung UniversityCompleted
-
University of HawaiiNational Heart, Lung, and Blood Institute (NHLBI); National Association of... and other collaboratorsNot yet recruitingDyslipidemia | Pre-diabetes | Type 2 Diabetes Mellitus (T2DM) | Hypertension (HTN) | Overweight (BMI > 25) | Weight Loss Trial | Cardiometabolic ConditionsUnited States